Citations

Clear

959 citation(s) found for "Service, F J".

Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin
Rizza, Robert A., Haymond, Morey W. , Verdonk, C., Mandarino, Lawrence J. , Miles, John M, Service, F John, Gerich, John E., Miles, John M

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 30 | Issue: 5 | Pages: 377-381

10.2337/diab.30.5.377 | PMID 6262168 Get It

To determine the mechanism by which hyperinsulinemia causes hypoglycemia in insulinoma patients, rates of glucose production and utilization, and circulating levels of insulin, glucagon, alanine, lactate, and glycerol were measured in 6 insulinoma patients during development of fasting hypoglycemia and in 8 normal volunteers studied over an identical interval. Initially, insulinoma patients had a greater plasma insulin (42 ± 9 versus 15 ± 1 μU/ml) and glucagon levels (214 ± 31 versus 158 ± 21 pg/ml) than normal subjects, P < 0.05, but their plasma glucose levels (81 ± 4 mg/dl) and rates of glucose production and utilization (1.71 ± 0.08 and 1.74 ± 0.08 mg/kg min, respectively) were not significantly different from those of normal subjects (93 ± 2 mg/dl, 1.93 / 0.11, and 1.92 ± 0.13 mg/kg · min, respectively). During a subsequent 8-h fast, glucose production and glucose utilization decreased in both groups, but more markedly in insulinoma patients. Since glucose utilization exceeded glucose production to a greater extent in insulinoma patients than in normal subjects, plasma glucose decreased to 44 ± 3 mg/dl in insulinoma patients, but only to 84 ± 1 mg/dl in normal subjects (P < 0.001). Glucose utilization in insulinoma patients never exceeded that of normal subjects. These results demonstrate that fasting hypoglycemia in the insulinoma patients is usually due to suppression of glucose production rather than to acceleration of glucose utilization, as is widely thought. A direct effect of insulin on the liver is probably responsible, since circulating levels of gluconeogenic precursors are normal and since plasma glucagon increases during development of hypoglycemia in insulinoma patients.
Twice-Daily Subcutaneous Injection of Kisspeptin-54 Does Not Abolish Menstrual Cyclicity in Healthy Female Volunteers
Jayasena, Channa , Comninos, Alexander , Nijher, Gurjinder, Abbara, Ali , Silva, A. De, Veldhuis, Johannes D. , Ratnasabapathy, Risheka , Izzi‐Engbeaya, Chioma , Lim, Adrian , Patel, Darshan , Ghatei, Mohammad A., Bloom, Stephen R. , Dhillo, Waljit S. , Jayasena, Channa N

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 13, 2013 | Volume: 98 | Issue: 11 | Pages: 4464-4474

10.1210/jc.2013-1069 | PMID 24030945 Get It

Background: Kisspeptin is a critical hypothalamic regulator of reproductive function. Chronic kisspeptin administration causes profound tachyphylaxis in male monkeys and in women with functional hypothalamic amenorrhea. The pharmacological effects of chronic kisspeptin exposure in healthy women with normal menstrual cycles have not been studied previously. Aim: Our aim was to determine the effects of follicular-phase kisspeptin-54 treatment on menstrual cyclicity in healthy women. Methods: We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7–14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatility, and acute sensitivity to GnRH and kisspeptin-54 injection were performed. Results: Menstrual cyclicity persisted in all women after follicular-phase kisspeptin-54 treatment. Chronic exposure to kisspeptin-54 did not abolish acute stimulation of LH after injection of kisspeptin-54 or GnRH. In addition, kisspeptin-54 treatment was associated with a shorter mean length of the menstrual cycle (mean length of menstrual cycle was 28.6 ± 1.4 days with saline vs 26.8 ± 3.1 days with kisspeptin, P < .01), earlier onset of highest recorded serum LH (mean menstrual day of highest LH was 15.2 ± 1.3 with saline vs 13.0 ± 1.9 with kisspeptin, P < .05), and earlier onset of the luteal phase (mean menstrual day of progesterone increase was 18.0 ± 2.1 with saline vs 15.8 ± 0.9 with kisspeptin, P < .05). Conclusion: Our data suggest that 1 week of exogenous kisspeptin-54 does not abolish menstrual cyclicity in healthy women. Further work is needed to determine whether kisspeptin could be used to treat certain anovulatory disorders.
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Xu‐Monette, Zijun Y. , Møller, Michael , Tzankov, Alexandar , Montes‐Moreno, Santiago , Hu, Wenwei , Manyam, Ganiraju C. , Kristensen, Louise , Fan, Lei , Visco, Carlo , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Richards, Kristy L. , Choi, William W.L., Krieken, J. Han van , Huang, Qin , Huh, Jooryung , Ferreri, Andrés J.M. , Zhao, Xiaoying , Bueso‐Ramos, Carlos E. , Wang, Sa A. , Winter, Jane N. , Piris, Miguel Á. , Medeiros, L. Jeffrey , Young, Ken H. , Bhagat, Govind , Hsi, Eric D. , Ai, Weiyun Z. , Ponzoni, Maurilio , Wu, Lin , Go, Ronald S. , Li, Yong , Møller, Michael Boe , Winter, Jane N , Tzankov, Alexandar , Dybkaer, Karen , van Krieken, J Han , Young, Ken H , Piris, Miguel , Medeiros, L Jeffrey , Zu, Youli , Montes-Moreno, Santiago , Xu-Monette, Zijun Y

Mayo Clinic

Blood | August 28, 2013 | Volume: 122 | Issue: 15 | Pages: 2630-2640

10.1182/blood-2012-12-473702 | PMID 23982177 Get It

Key PointsPhenotypic and genotypic profiling of MDM2 in DLBCL. MDM2 as a negative regulator of p53 tumor suppressor function.
Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia
Kocarnik, Jonathan , Lindor, Noralane M. , Chang‐Claude, Jenny , Caberto, Christian, Love, Shelly-Ann, Slattery, Martha L. , Hindorff, Lucia A. , Park, Sungshim Lani, Schumacher, Fredrick R. , Hoffmeister, Michael , Duggan, David , Hou, Lifang , Carlson, Chris , Carty, Cara L. , Mann, Sue, Giovannucci, Edward L. , Fuchs, Charles S. , Jenkins, Mark A. , Haile, Robert W. , Conti, David V. , Potter, John D. , Caan, Bette J. , Hayes, Richard B. , Berndt, Sonja I. , Küry, Sébastien , Bezieau, Stéphane , Ambite, José Luis , Kumaraguruparan, Gowri, Richardson, Danielle , Goodloe, Robert, Dilks, Holli H., Baker, Paxton, Zanke, Brent W., Lemire, Mathieu , Gallinger, Steven , Jiao, Shuo , Harrison, Tabitha A. , Seminara, Daniela, Haiman, Christopher A. , Hutter, Carolyn M., Crawford, Dana C. , Heiss, Gerardo , Brenner, Hermann , Bush, William S. , Casey, Graham , Peters, Ulrike , Cheng, Iona C. , Dumitrescu, Logan , Avery, Christy L. , Chan, Andrew T. , Baron, John A. , Kraft, Peter , Butler, Anne Marie E. , Monroe, Kristine R. , Lin, Yi , Ma, Jing , Newcomb, Polly A. , Hopper, John L. , Campbell, Peter T. , Schoen, Robert E. , Chanock, Stephen Jacob , Hsu, Li , Kooperberg, Charles , Wilkens, Lynne R. , White, Emily E. , Hudson, Thomas J , Marchand, Loı̈c Le , Hoffmeister, Michael , Jenkins, Mark A , Haile, Robert W , Harrison, Tabitha A , Potter, John D , Kury, Sebastien , Brenner, Hermann , Hayes, Richard B , Bézieau, Stéphane , Conti, David V , Hou, Lifang , Caan, Bette J , Bush, William S

Mayo Clinic

Gut | August 10, 2013 | Volume: 63 | Issue: 5 | Pages: 800-807

10.1136/gutjnl-2013-305189 | PMID 23935004 Get It

Objective Genome-wide association studies have identified a large number of single nucleotide polymorphisms (SNPs) associated with a wide array of cancer sites. Several of these variants demonstrate associations with multiple cancers, suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesised that SNPs previously associated with other cancers may additionally be associated with colorectal cancer. In a large-scale study, we examined 171 SNPs previously associated with 18 different cancers for their associations with colorectal cancer. Design We examined 13 338 colorectal cancer cases and 40 967 controls from three consortia: Population Architecture using Genomics and Epidemiology (PAGE), Genetic Epidemiology of Colorectal Cancer (GECCO), and the Colon Cancer Family Registry (CCFR). Study-specific logistic regression results, adjusted for age, sex, principal components of genetic ancestry, and/or study specific factors (as relevant) were combined using fixed-effect meta-analyses to evaluate the association between each SNP and colorectal cancer risk. A Bonferroni-corrected p value of 2.92×10 −4 was used to determine statistical significance of the associations. Results Two correlated SNPs—rs10090154 and rs4242382—in Region 1 of chromosome 8q24, a prostate cancer susceptibility region, demonstrated statistically significant associations with colorectal cancer risk. The most significant association was observed with rs4242382 (meta-analysis OR=1.12; 95% CI 1.07 to 1.18; p=1.74×10 −5 ), which also demonstrated similar associations across racial/ethnic populations and anatomical sub-sites. Conclusions This is the first study to clearly demonstrate Region 1 of chromosome 8q24 as a susceptibility locus for colorectal cancer; thus, adding colorectal cancer to the list of cancer sites linked to this particular multicancer risk region at 8q24.
GABA B receptor autoantibody frequency in service serologic evaluation
Jeffery, Oliver J., Lennon, Vanda A. , Pittock, Sean J. , Gregory, Jeremy K., McKeon, Andrew , Britton, Jeffrey W. , Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology | August 8, 2013 | Volume: 81 | Issue: 10 | Pages: 882-887

10.1212/wnl.0b013e3182a35271 | PMID 23925760 Get It

Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bhangu, Aneel , Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Hompes, Roel , Jeys, Lee , Jenkins, John T. , Kiran, Ravi P. , Koh, Cherry , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Patel, Uday , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tan, Emile , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Collaborative, The Beyond TME, Ali, Simak , Brown, Gina , Wilt, Johannes H.W. de , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Glynne‐Jones, Rob , Goldin, Robert , Harji, Deena Pravin , Heriot, Alexander G. , Marshall, Michelle Berger , Radley, Simon, Solomon, Michael J. , Jeys, Lee M

Mayo Clinic

British Journal of Surgery | June 21, 2013 | Volume: 100 | Issue: 8 | Pages: E1-E33

10.1002/bjs.9192_1 | PMID 23901427 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score
Farooq, Vasim , Bourantas, Christos V. , Zhang, Yao‐Jun , Muramatsu, Takashi , Feldman, Ted , Holmes, David R. , Mack, Michael J. , Morice, Marie Claude, Ståhle, Elisabeth , Colombo, Antonio , Vries, Ton de, Morel, Marie-angèle , Dawkins, Keith D., Mohr, Friedrich W., Serruys, Patrick W. , Morice, Marie‐Claude, Kappetein, A. Pieter

Mayo Clinic

Circulation | June 13, 2013 | Volume: 128 | Issue: 2 | Pages: 141-151

10.1161/circulationaha.113.001803 | PMID 23766350 Get It

Background— The residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Score is an objective measure of the degree and complexity of residual stenosis after percutaneous coronary intervention (PCI). Methods and Results— In the randomized PCI cohort of the SYNTAX Trial (n=903), the baseline and residual SYNTAX Scores were calculated. Subjects with a residual SYNTAX Score of 0 were defined as having undergone complete revascularization (CR), and a residual SYNTAX Score >0 as incomplete revascularization (ICR). Five-year clinical outcomes were stratified by CR and ICR (tertiles of the residual SYNTAX Score: >0–4, >4–8, and >8). In the PCI cohort, the mean baseline and residual SYNTAX Scores were 28.4±11.5 and 4.5±6.9, respectively. The mean Δ SYNTAX Score (representative of the burden of disease removed by PCI) was 23.8±10.9. The residual SYNTAX Score was distributed as follows: CR, 0 (n=386, 42.7%); ICR, >0 to 4 (n=184, 20.4%), >4 to 8 (n=167, 18.5%), >8 (n=153, 16.9%). A progressively higher residual SYNTAX Score was shown to be a surrogate marker of increasing clinical comorbidity and anatomic complexity. Subjects with CR or residual SYNTAX Scores ≤8 had comparable 5-year mortality (CR, 8.5%; residual SYNTAX Score >0–4, 8.7%; >4–8, 11.4%; P =0.60). A residual SYNTAX Score >8 was associated with 35.3% all-cause mortality at 5-years ( P <0.001). Stratified analyses in the predefined medical treated diabetic and left main subgroups yielded similar results. Conclusions— The residual SYNTAX Score was shown to be a powerful indicator of 5-year mortality in the SYNTAX Trial. The residual SYNTAX Score may aid in determining a reasonable level of revascularization. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00114972.
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Brown, Gina , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Wilt, Johannes H. W. de, Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Glynne‐Jones, R., Goldin, Robert , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Jenkins, John T. , Kiran, Ravi P. , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Solomon, Michael J. , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Coombes, R. Charles , Collaborative, The Beyond TME, Ali, Simak , Bhangu, Aneel , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Harji, Deena Pravin , Heriot, Alexander G. , Hompes, Roel , Jeys, Lee , Koh, Cherry , Marshall, Michelle Berger , Patel, Uday , Radley, Simon, Tan, Emile , Solomon, Michael J

Mayo Clinic

British Journal of Surgery | June 10, 2013 | Volume: 100 | Issue: 8 | Pages: 1009-1014

10.1002/bjs.9192 | PMID 23754654 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Patient and service user engagement in research: a systematic review and synthesized framework
Shippee, Nathan D. , Garces, Juan Pablo Domecq , Lopez, Gabriela J. Prutsky, Elraiyah, Tarig, Nabhan, Mohammed , Brito, Juan P. , Boehmer, Kasey B., Hasan, Rim, Firwana, Belal , Erwin, Patricia J., Montori, Víctor M. , Murad, M. Hassan , Domecq Garces, Juan Pablo, Prutsky Lopez, Gabriela J, Elraiyah, Tarig A, Boehmer, Kasey, López, Gabriela, Wang, Zhen , Murad, M Hassan , Montori, Victor M , Brito, Juan P , Domecq Graces, Juan Pablo , Shippee, Nathan

Mayo Clinic

Health Expectations | June 4, 2013 | Volume: 18 | Issue: 5 | Pages: 1151-1166

10.1111/hex.12090 | PMID 23731468 Get It

Abstract Background There is growing attention towards increasing patient and service user engagement ( PSUE ) in biomedical and health services research. Existing variations in language and design inhibit reporting and indexing, which are crucial to comparative effectiveness in determining best practices. Objective This paper utilizes a systematic review and environmental scan to derive an evidence‐based framework for PSUE . Design A metanarrative systematic review and environmental scan/manual search using scientific databases and other search engines, along with feedback from a patient advisory group ( PAG ). Eligible sources English‐language studies, commentaries, grey literature and other sources (including systematic and non‐systematic reviews) pertaining to patient and public involvement in biomedical and health services research. Data extracted Study description (e.g. participant demographics, research setting) and design, if applicable; frameworks, conceptualizations or planning schemes for PSUE ‐related endeavours; and methods for PSUE initiation and gathering patients'/service users' input or contributions. Results Overall, 202 sources were included and met eligibility criteria; 41 of these presented some framework or conceptualization of PSUE . Sources were synthesized into a two‐part framework for PSUE: (i) integral PSUE components include patient and service user initiation, reciprocal relationships, colearning and re‐assessment and feedback, (ii) sources describe PSUE at several research stages, within three larger phases: preparatory, execution and translational. Discussion and Conclusions Efforts at developing a solid evidence base on PSUE are limited by the non‐standard and non‐empirical nature of much of the literature. Our proposed two‐part framework provides a standard structure and language for reporting and indexing to support comparative effectiveness and optimize PSUE .